Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...

Some doctors are concerned that patients taking weight loss drugs like Wegovy may be losing too much lean mass. A combination ...

Patients who took an experimental drug from Eli Lilly & Co. together with Novo Nordisk A/S’s Wegovy maintained muscle while ...

Fueled by a sustained boom in sales of its diabetes and obesity products, Eli Lilly will become the world’s top-seller of prescription drugs by 2030 and will hold the top rung by a wide margin. | ...

Special Call (Lilly Investor Event at American Diabetes Association's (ADA) 85th Scientific Sessions) Conference June ...

Baron Funds, an investment management company, released its “Baron Fifth Avenue Growth Fund” first quarter 2025 investor ...

While Eli Lilly brushed off concerns about gastrointestinal side effects for oral weight loss candidate orforglipron, ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...

Eli Lilly is looking to approach regulators for approval of its once-weekly insulin for type 2 diabetes (T2D) after it proved ...

Eli Lilly (LLY) closed the most recent trading day at $770.64, moving +1.04% from the previous trading session. The stock's performance was ahead of the S&P 500's daily gain of 0.96%. Meanwhile, the ...

U.S. pharma companies should pay rather more of their corporate income tax in the U.S.—and start producing more of their best drugs in the U.S. as well.

The endocrinologist and researcher was one of several investigators who presented Phase 3 clinical trial results at the 85th Scientific Sessions of the American Diabetes Association for a long-lasting ...